The FDA recently ruled bluebird bio’s blood disorder therapy as effective, and William Blair analyst Raju Prasad is quoted on the implications for the company.
Equity Research
William Blair Analyst Raju Prasad Comments on Bluebird Bio in Reuters
Delivered to Your Inbox
Stay up-to-date with the latest William Blair news and insights
Our Latest News
Bentley Systems, Incorporated: Initiation of Research Coverage
William Blair initiated research coverage of Bentley Systems, Incorporated (BSY $51.19), a leading provider of design, build, operate, and maintain software for the infrastructure industry.
Read moreSolid Biosciences Inc.: Initiation of Research Coverage
William Blair initiated research coverage of Solid Biosciences Inc. (SLDB $13.57), a development-stage biopharmaceutical company focused on gene therapies for rare neuromuscular and cardiac diseases.
Read moreThree Issues in Zambia
Dan Wood speaks to us from Zambia, where restructuring, mining, and currency appreciation are top of mind for emerging markets debt investors.
Watch the video